Schroeder J R, Saah A J, Hoover D R, Margolick J B, Ambinder R F, Martinez-Maza O, Breen E C, Jacobson L P, Variakojis D, Rowe D T, Armenian H K
Department of Epidemiology, Johns Hopkins University Baltimore, Maryland 21205, USA.
Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84.
The cytokine soluble CD23 (sCD23) has been shown to act as a B cell growth factor and to be elevated in serum prior to development of AIDS-related non-Hodgkin's lymphoma (AIDS NHL). To further characterize the elevation of serum sCD23 in AIDS NHL patients and investigate its potential as a diagnostic test, a matched case-control study of AIDS NHL (n = 101) was nested within the Multicenter AIDS Cohort Study. Serum sCD23 was measured in cases' and controls' serum specimens at three different time periods (0-6, 6-12, and 12-18 months) and CD4+ thresholds (0-99, 100-199, and 200-299 cells/microl) prior to the case's NHL diagnosis. Changes in serum sCD23 over time were examined in AIDS NHL cases relative to controls, and t tests were performed to determine whether cases' serum sCD23 exceeded that of controls at each time period and CD4+ threshold. Overall, cases' median serum sCD23 levels were approximately double those of controls. Serum sCD23 concentration was positively correlated with lymphocyte counts for both cases and controls. The difference in cases' and controls' serum sCD23 levels became greater as AIDS NHL diagnosis date approached: in the 18 months preceding the case's NHL diagnosis, serum sCD23 was stable in cases but dropped in controls. Although this difference was statistically significant (P < 0.05), it was not clinically significant. It is unlikely that serum sCD23 would make a useful test for AIDS NHL because the magnitude of the difference between cases and controls was small and there was no change in serum sCD23 in cases that would indicate disease.
细胞因子可溶性CD23（sCD23）已被证明可作为B细胞生长因子，且在艾滋病相关非霍奇金淋巴瘤（AIDS NHL）发生之前血清中水平会升高。为进一步明确AIDS NHL患者血清sCD23升高的情况并研究其作为诊断检测指标的潜力，在多中心艾滋病队列研究中开展了一项AIDS NHL（n = 101）的匹配病例对照研究。在病例组和对照组的血清标本中，于三个不同时间段（0 - 6个月、6 - 12个月和12 - 18个月）以及病例组NHL诊断前的不同CD4 + 阈值（0 - 99个细胞/微升、100 - 199个细胞/微升和200 - 299个细胞/微升）测量血清sCD23。相对于对照组，检测了AIDS NHL病例血清sCD23随时间的变化情况，并进行t检验以确定在每个时间段和CD4 + 阈值下病例组血清sCD23是否超过对照组。总体而言，病例组血清sCD23中位数水平约为对照组的两倍。病例组和对照组的血清sCD23浓度均与淋巴细胞计数呈正相关。随着AIDS NHL诊断日期临近，病例组和对照组血清sCD23水平的差异变得更大：在病例组NHL诊断前的18个月里，病例组血清sCD23保持稳定，而对照组则下降。尽管这种差异具有统计学意义（P < 0.05），但在临床上并不显著。血清sCD23不太可能成为AIDS NHL的有效检测指标，因为病例组和对照组之间的差异幅度较小，且病例组血清sCD23没有出现表明疾病的变化。
